MUMBAI, April 18- India's Glenmark Pharmaceuticals Ltd is recalling some 2,900 bottles of its stomach ulcer drug ranitidine in the United States after a foreign tablet was found in one of the bottles.
In the short term, that is expected to benefit larger global competitors, such as Teva Pharmaceutical Industries Ltd, Actavis Plc and Mylan Inc, which will be called upon to supply drugs no longer available from some of their rivals in India, they said.
WASHINGTON/ NEW YORK, March 18- Some U.S. doctors are becoming concerned about the quality of generic drugs supplied by Indian manufacturers following a flurry of recalls and import bans by the Food and Drug Administration.
*Surpasses previous high set on Jan. 10, 2008. MUMBAI, Nov 1- India's benchmark BSE index surged to a record on Friday as blue chips rallied on the back of strong foreign buying, in a remarkable turnaround from two months earlier, when the rupee hit record lows and threatened a crisis of confidence.
U.S. stock index futures signaled a lower open on Tuesday, as fears that China's central bank will not provide stimulus to boost its economy saw the Shanghai Composite fall to a one-week low.
The Food and Drug Administration on Wednesday asked Teva Pharmaceuticals to withdraw its drug Budeprion XL 300 after testing showed the drug did not properly release its key ingredient.
With violence in the Middle East triggering a rotation out of emerging markets, how should you trade, especially if you still believe in the EM story?
Ron Shah Of Jina Ventures suggests putting money to work overseas in these 10 stocks.
Indian stocks have been sliding since the New Year amid inflation fears but there are still places where investors can get in, said Ron Shah, managing partner at Jina Ventures.
With President Obama visiting the Subcontinent, Ron Shah of Jina Ventures recommends playing these Indian companies in the long-term.
India's stock market has jumped almost 19% over the past year, far outpacing the Dow Jones Industrial Average, and it may not be done yet....A report from TheStreet.
With Barron’s turning very bullish on generic drugmaker Mylan Labs, should you put money to work in the generic space?
It seems new taxes on outside investors looking to play Brazil can’t dampen enthusiasm about emerging markets!
A decisive win by India's capitalism party over rival communists triggered the largest gains in stocks in about two decades. How should you be trading?
Indian stocks that trade in the U.S. are up double digits as stock trading in India was halted for the first time because of a surge in stock prices on the big election victory for Prime Minister Singh's Congress Party.
Today was really ugly for biotech. The only large-cap sector stock to trade higher--and significantly--was Genentech because it's being bolstered by Roche's bond sale and increasing speculation the Swiss drugmaker is gonna have to raise its bid for DNA.
Recently, there've been scattered media reports about some drugs polluting India's slum water in alarming concentrations, according to some experts. Separately, yesterday, the U.S. Food and Drug Administration announced it's keeping India generic drugmaker Ranbaxy in the penalty box while it continues looking into whether the company fudged some data.
India’s economy is the twelfth largest in the world in terms of GDP measured in US dollars, with a solid $1.10 trillion in GDP for 2007. Here are stats and stocks from India.
Big pharma analysts keep close tabs on prescription trends. Many of them issue weekly reports to clients about what's up, what's down, what's holding steady. Investors use the data as a leading indicator for what quarterly sales and profits might look like. So, check out what A.G. Edwards' Joe Tooley is writing in his most recent "Weekly Prescription Trends" report.Tooley titles it, "Lipitor Continues to Decline, Can Simvastatin (the generic version of Zocor) Surpass It?"
Good morning everyone. Here's a look at the current standings on our finalist leaderboard--as we head into the last week of the contest. Steven Lee (pictured) holds onto first place--and he's taking a rather conservative approach by remaining all in cash and hoping that Serge Amelyan's all-in bet on Terra Industries doesn't pan out. Serge moves back into 2nd place from 4th on his Intuit trade up on strong earnings.